OSAKA, Japan, April 1, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced Shionogi Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Ryuichi Kume, Ph.D.; hereafter "Shionogi Pharma") , a wholly owned subsidiary of Shionogi, completed to implement an absorption-type merger with Nagase Medicals Co., Ltd. (Head Office: Itami, Hyogo, Japan; Representative Director and President: Mitsuru Akasaka; hereafter “Nagase Medicals”), a wholly owned subsidiary of Shionogi Pharma, on April 1, 2022.
Based on a press release "Notice Regarding Reorganization of Subsidiary through Company Merger" issued on November 30, 2021, Shionogi Pharma today executed an absorption-type merger of its consolidated subsidiary, Nagase Medicals.
Through merged with Nagase Medicals establishing the new business foundation, Shionogi Pharma will aim to create the contract manufacturing of the diverse modality by the manufacturing technology of high pharmacological activity APIs, solid preparations and injectable preparations in the strength of both companies. Shionogi Pharma will also aim to establish a new drug manufacturing platform through the development of continuous production technology for APIs and pharmaceutical formulations.
Shionogi Pharma will provide higher quality and prompt full-range contract manufacturing, further increase customer value, and aim for further growth as a technological innovation-focused manufacturing company.
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
About Shionogi Pharma
Shionogi Pharma has expanded its business of manufacturing, sale, analytical testing and pharmaceutical engineering of ethical drugs and investigational drugs under its mission to “promote health and create new value to benefit all of society, providing highly valued healthcare products and services through the development of new technologies”. In addition, Shionogi Pharma aims to become the most trusted one-stop CDMO* meeting the needs of all our customers, not limited to the Shionogi group.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html